Company / R&D Expense
Tarsus Pharmaceuticals, Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$64.3M
FY2025
5-year range
$41.7M / $64.3M
FY2021-FY2025
Trend
+20.5%
vs FY2024
Sector context
#170 of 210
Health Care
What the data says
Tarsus Pharmaceuticals, Inc.'s r&d expense of $64M is lower than 81% of companies in the Health Care sector (FY2025). R&D Expense has increased for 3 consecutive years, from $42M in FY2022 to $64M in FY2025.
Based on SEC 10-K filings.
$64M in FY2025 with a 5-year CAGR of +27.9%.
Improved from $50M to $64M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.5%
- 5-Year CAGR
- +27.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 210This company $64.3M Sector average $644.1M
▼
-90.0% below sector average
Key checks
Key Insights
- Tarsus Pharmaceuticals, Inc.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +27.9%, indicating consistent growth.
- In FY2025, r&d expense increased 20.5% year-over-year.
- Ranks #170 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $64.3M | +20.5% |
| FY2024 | $53.4M | +6.1% |
| FY2023 | $50.3M | +20.6% |
| FY2022 | $41.7M | +0.0% |
| FY2021 | $41.7M | +121.6% |
| FY2020 | $18.8M | +495.4% |
| FY2019 | $3.2M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026